2022
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, O'Dwyer P, Benson A. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). Journal Of Clinical Oncology 2022, 41: 1359-1369. PMID: 36260828, PMCID: PMC9995105, DOI: 10.1200/jco.22.01013.Peer-Reviewed Original ResearchConceptsAdvanced pancreatic neuroendocrine tumorsProgression-free survivalPancreatic neuroendocrine tumorsMedian progression-free survivalPrimary end pointNeuroendocrine tumorsResponse rateObjective responseOverall survivalRandomized studyIntermediate-grade pancreatic neuroendocrine tumorsLonger progression-free survivalEnd pointMGMT deficiencyMedian overall survivalPrimary analysis populationKey eligibility criteriaPhase II trialSmall prospective studiesHigh response rateMethylguanine methyltransferaseCapecitabine/Eligible patientsSecondary endpointsII trial
2016
Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors
Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin–Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors. Pancreas 2016, 45: 1394-1400. PMID: 27171514, DOI: 10.1097/mpa.0000000000000659.Peer-Reviewed Original ResearchConceptsRadiographic response rateAdvanced neuroendocrine tumorsPrimary end pointProgression-free survivalNeuroendocrine tumorsPancreatic neuroendocrine tumorsNeuroendocrine carcinomaProspective phase II studyB studyEnd pointProlonged disease stabilityPhase II studyEffectiveness of bevacizumabDifferentiated neuroendocrine carcinomaPredictable toxicityRR-18Maintenance therapyDisease stabilityII studyRadiographic responsePatientsResponse rateNET subtypesBevacizumabMonths
2012
Capecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-Induced Chest Pain Relieved by Diltiazem. The American Journal Of Cardiology 2012, 110: 1623-1626. PMID: 22939579, DOI: 10.1016/j.amjcard.2012.07.026.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntimetabolites, AntineoplasticAnus NeoplasmsCalcium Channel BlockersCapecitabineCarcinoma, Squamous CellChest PainColorectal NeoplasmsCoronary VasospasmDeoxycytidineDiltiazemElectrocardiographyFemaleFluorouracilFollow-Up StudiesHumansMaleMiddle AgedProdrugsSecondary PreventionTreatment OutcomeConceptsChest painAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarctionAnal squamous cell carcinomaSignificant coronary artery diseaseDiscontinuation of capecitabineElevation myocardial infarctionCoronary artery diseasePrimary colorectal adenocarcinomaSquamous cell carcinomaIschemia evaluationSecondary prophylaxisTroponin elevationArtery diseaseInitial presentationSustained reliefElectrocardiographic findingsCell carcinomaMyocardial infarctionColorectal adenocarcinomaPainPatientsChemotherapeutic agentsNovel management strategiesCapecitabine